GlaxoSmithKline: VIIV launches study on bi-therapy
(CercleFinance.com) - GlaxoSmithKline announced on Monday that its HIV treatment subsidiary, ViiV Healthcare, has started a study to evaluate the best possible administration of a long-term injectable HIV drug.
For one year, ViiV teams and healthcare professionals from 18 clinical centres in France, Spain, Belgium, Germany and the Netherlands will study the best way to inject this bi-therapy, consisting of a combination of cabotegravir and rilpivirine.
This long-acting treatment is intended to replace the daily intake of tablets taken orally.
The first results of the study are expected in 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
For one year, ViiV teams and healthcare professionals from 18 clinical centres in France, Spain, Belgium, Germany and the Netherlands will study the best way to inject this bi-therapy, consisting of a combination of cabotegravir and rilpivirine.
This long-acting treatment is intended to replace the daily intake of tablets taken orally.
The first results of the study are expected in 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.